Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Bristol-Myers says COO Caforio to take over as CEO

January 21, 2015
Life sciences
Bristol-Myers Squibb will soon have a new CEO. Chief Operating Officer Giovanni Caforio will take over the top exec job on May 5, when 64-year-old Lamberto Andreotti steps down from the role he has held for 5 years and takes over instead as executive chairman of the board.
 
“I also want to express my excitement that Giovanni has been appointed to succeed me as CEO,” Andreotti said in statement released by BMS late Tuesday. “I have a high level of confidence in Giovanni that is shared by everyone who has seen him consistently and successfully drive performance.”
 
Caforio is a 15-year veteran of the company who started at BMS as vice president and general manager in Italy. He is a medical doctor who got his MD from the University of Rome and started in the industry in medical affairs at Abbott Laboratories ($ABT). He has held a number of roles at BMS, including in its global oncology group, where he is said to have helped build its acknowledged leadership role in immuno-oncology.
 
That is the company’s beacon right now and the reason that JP Morgan analysts recently told investors they should be interested in BMS in 2015. They said that while the drugmaker’s shares have already escalated on the anticipated immuno-oncology sales from Yervoy and the newly FDA-approved Opdivo, they see “the potential for further upside to this figure (and BMY shares) from a number of important updates.”
 
It will be up to Caforio to make the most of this upside potential, but it was Andreotti who put the pieces into place. For his efforts he has been highly compensated, hitting $20.85 million in total compensation in 2013, making him the third best-paid biopharma CEO. There have been some stumbles with the successes. He was in charge for the acquisition of Amylin Pharmaceuticals to expand a diabetes partnership with AstraZeneca ($AZN), then promptly bailed out of that partnership in 2013. The company scrapped a few development programs as well, including early hepatitis C work and neuroscience.
 
By Eric Palmer
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

Read more
April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

Read more
April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

Read more
More news

How can we help you?

We're easy to reach